Results 21 to 30 of about 6,849 (203)
Y Grace Wang,1 Khadra Benmedjahed,2 Jérémy Lambert,2 Christopher J Evans,3 Steve Hwang,3 Jed Black,1,4 Murray W Johns5 1Clinical Development, Jazz Pharmaceuticals, Palo Alto, CA, USA; 2Patient-Centered Outcomes, Mapi, Lyon, France ...
Wang YG +6 more
doaj +1 more source
Narcolepsy/Cataplexy and Occult Neuroblastoma
Investigators at the University of Chicago and Northwestern University, Chicago, IL; University Hospital Southampton, UK; and Kiev Paediatric Hospital, Ukraine, report three children with narcolepsy and cataplexy subsequently diagnosed with neuroblastoma.
J Gordon Millichap
doaj +2 more sources
The use of citalopram for the treatment of cataplexy$
This is a series of cases describing the use of citalopram for the treatment of cataplexy in patients with narcolepsy. Cataplexy is the most specific symptom of narcolepsy, being characterized by a sudden and temporary loss of muscle tonus, triggered by ...
Hassana de Almeida Fonseca +10 more
doaj +4 more sources
Ambulatory video-EEG-EMG monitoring and analysis during cataplexy in narcolepsy
Objective To comprehensively analyze the clinical and electroneurophysiological characteristics during the process of cataplexy by dynamic video?EEG?EMG monitoring.
Bei HUANG +4 more
doaj +1 more source
Therapeutic Prospects of Ketamine for Cataplexy in Narcolepsy Type 1: Evidence from a Human Case and a Murine Model. [PDF]
Narcolepsy type 1 is characterized by cataplexy, for which current treatments targeting monoaminergic, histaminergic, and GABAergic pathways may be ineffective or poorly tolerated. We report the case of a 34‐year‐old man with narcolepsy type 1, intolerant to standard therapies, who experienced marked and sustained cataplexy reduction with morning ...
Ricordeau F +8 more
europepmc +2 more sources
Postmortem Evidence of CRH Neuron Reduction in Narcolepsy Without Cataplexy With Borderline Hypocretin-1 Levels. [PDF]
ABSTRACT Narcolepsy is classified as type 1 (NT1) or type 2 (NT2) mainly according to hypocretin deficiency rather than cataplexy. While CRH neuron loss in the PVN has been described in NT1, it remains unclear whether similar changes occur in narcolepsy without cataplexy.
Shan L +5 more
europepmc +2 more sources
Background Cataplexy is a loss of muscle tone that can lead to postural collapse, disturbing the daily life of narcolepsy patients; it is often triggered by positive emotions such as laughter in human patients.
Mayuko Yoshida +2 more
doaj +1 more source
COVID-19-Induced Narcolepsy Type I With Cataplexy: A Short Report. [PDF]
ABSTRACT Narcolepsy type I is a rare neurological sleep disorder characterised by chronic excessive daytime sleepiness, cataplexy, and low orexin (hypocretin) levels. Infection with SARS‐CoV‐2 has been linked to neurological and neuropsychiatric sequelae, but cases of post‐COVID narcolepsy remain extremely uncommon.
Merinder TV +2 more
europepmc +2 more sources
Activity of putative orexin neurons during cataplexy
It is unclear why orexin-deficient animals, but not wild-type mice, show cataplexy. The current hypothesis predicts simultaneous excitation of cataplexy-inhibiting orexin neurons and cataplexy-inducing amygdala neurons.
Shi Zhou +7 more
doaj +1 more source
Cerebrospinal fluid orexin testing in Australians with narcolepsy type 1. [PDF]
Abstract A clinical diagnosis of narcolepsy type 1 can be challenging, particularly in relation to cataplexy. Despite its specificity, cerebrospinal fluid (CSF) orexin testing is under‐utilised in Australasia. We describe the use of CSF orexin testing in 15 clinically indicated patients from two sleep centres, highlighting its utility in the ...
Fernando M +8 more
europepmc +2 more sources

